Eleven out of twelve Type 1 diabetes patients treated with intralymphatic Diamyd® are in Partial Remission at 15 months
Diamyd Medical announces that a further analysis ahead of the upcoming conference 1st Antigen Specific Immune Tolerance Europe in London 11-12 December shows that 92% (11 out of 12) of the DIAGNODE-1 trial participants are in Partial Remission at 15 months from start of the trial. This can be compared to a large international study in 3657 children and adolescents with type 1 diabetes, where approximately 20% of the patients were in partial remission 12 to 18 months after diagnosis. Partial remission in type 1 diabetes is characterized by low external insulin requirement and near to normal